Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals

This work aims to evaluate the therapeutic survey of adverse events during antiviral treatment of hepatitis in the three major University Hospitals in Abidjan. A retrospective cross-sectional descriptive study of 203 patients from August 1, 2015, to July 31, 2018, enumerated adverse events during antiviral treatments, drugs used for their management, and their clinical or biological impact. The following was seen: hematological disorders during treatment with pegylated interferon α-2a (88.61%) and ribavirin (77.55%), pain syndrome when using pegylated interferon α-2a (90.5%), and digestive disorders while taking sofosbuvir (60.71%) and daclatasvir (66.67%). Hematological disorders were managed with filgrastim for neutropenia and oral iron or blood transfusion for anemia and/or thrombocytopenia. Pain syndrome was treated with paracetamol. As for digestive disorders, they were most often managed with activated charcoal. Correction of the adverse events was made either using causal treatment or using symptomatic drugs. However, some drugs, in particular hematopoietic factors, have been less used due to their costs.